MACROGENICS INC — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 76/100
What the filing says
MacroGenics completed the sale of its GMP drug substance manufacturing operations and CDMO business to Bora Pharmaceuticals Co., Ltd. for $122.5 million in cash (before transaction fees), effective June 30, 2026. The transaction includes transfer of manufacturing facilities in Rockville, MD and warehouse in Frederick, MD, with approximately 140 MacroGenics employees hired by Bora. MacroGenics retains a supply agreement with Bora for its internal pipeline manufacturing needs and is eligible for up to $5 million in contingent consideration upon achievement of manufacturing milestones in 2027-2028.
Why this rating
Sale proceeds of $122.5M represent 166% of company's $73.9M market cap—transformational liquidity event. Divests non-core CDMO operations, allows focus on core antibody-based cancer therapeutics pipeline. Reduces operating costs (140 employees transferred) but creates supply dependency on Bora. Material near-term positive for cash runway.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.